| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.002 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | manumycin A | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | 0.12 | 0.003 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.004 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.093 | 0.004 |
| mRNA | Nutlin-3 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.004 |
| mRNA | DBeQ | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | thapsigargin | GDSC1000 | pan-cancer | AAC | -0.11 | 0.004 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.098 | 0.005 |